The Center for Breakthrough Medicines (CBM) has appointed Mandy Conver as Senior Vice President (SVP) of Business Development for Testing & Analytics, and Jennifer Manning as SVP of Global Strategic Partnerships.
Mandy Conver (above) will tap into her 20-plus years of diverse experience in the biotechnology and BioPharma industries to strategically lead all organic and new business development opportunities for CBM's Testing & Analytics division. She will be responsible for leading and directing a team of highly technical Business Development professionals to repeated success while driving revenue growth.
Most recently, Conver led the successful launch of QIAGEN's QIAcuity Digital PCR portfolio in North America, where she oversaw market strategy and commercial activities, including creation of a specialized commercial team and customized training for a large-matrix sales organization. Additionally, she also negotiated strategic alliances and heavily influenced portfolio evolution that led to QIAGEN achieving widespread adoption of the platform throughout the cell and gene therapy field.
Conver earned her bachelor's in chemistry from The George Washington University.
With more than 25 years of bioprocessing and cell and gene therapy experience, Jennifer Manning (right) will negotiate, develop and lead strategic partnerships with academic institutions, private equity and venture capital firms, and large pharma in her new role as SVP of Global Strategic Partnerships at CBM.
Additionally, she will help set the strategy for growing CBM revenue, establish senior-level relationships with partners, and build a team of Strategic Account Directors ensuring CBM partners have access to its technologies and services, while focusing on establishing and nurturing thoughtful, long-term collaborations.
Most recently, Manning built and led the North American Advanced Therapy Commercial Development Team at Fujifilm Diosynth Biotechnologies, where she was responsible for the growth of the viral vector, recombinant vaccine, and oncolytic virus businesses. Previous roles and responsibilities include advancing global capabilities for industry leading CDMOs such as Lonza, DSM Biologics, Alcami Corporation, and Patheon and helping to build and lead the sales training department at Human Genome Sciences for the successful launch of BENLYSTA.
Manning earned her bachelor's degree in biological sciences from Clemson University and a Master of Public Administration, Health Policy and Management from New York University.
Based in Philadelphia's Cellicon Valley. CBM offers pre-clinical through commercial manufacturing capabilities including process development, plasmid DNA, viral vector manufacturing, cell banking, cell processing, and a full suite of complementary testing and analytical capabilities.